Pharmacological activation of the STING (stimulator of interferon genes)–controlled innate immune pathway is a promising therapeutic strategy for cancer. Here we report the identification of MSA-2, an orally available non-nucleotide human STING agonist. In syngeneic mouse tumor models, subcutaneous and oral MSA-2 regimens were well tolerated and stimulated interferon-β secretion in tumors, induced tumor regression with durable antitumor immunity, and synergized with anti–PD-1 therapy. Experimental and theoretical analyses showed that MSA-2 exists as interconverting monomers and dimers in solution, but only dimers bind and activate STING. This model was validated by using synthetic covalent MSA-2 dimers, which were potent agonists. Cellular potency of MSA-2 increased upon extracellular acidification, which mimics the tumor microenvironment. These properties appear to underpin the favorable activity and tolerability profiles of effective systemic administration of MSA-2.

Facile and mass production of intrinsic and defect-free 2D QSs from bulk layered materials is achieved via a unified top-down method.

Mass production of two-dimensional quantum sheets (2D QSs) is highly desired to fully exploit their properties. Herein, we present a general strategy for the high-yield production of molybdenum disulfide (MoS) and tungsten disulfide (WS) QSs by a sequential combination of salt-assisted ball-milling and sonication-assisted solvent exfoliation of their bulk materials. Such a strategy enables reproducible production of intrinsic and defect-free MoS and WS QSs with exceedingly high yields of 25.5 and 20.1 wt %, respectively. By precipitation-redispersion treatment, the QSs can be redispersed in a wide range of solvents with redispersion concentration up to 20 mg/mL or even higher. Remarkable nonlinear absorption saturation is demonstrated in the QSs-poly(methyl methacrylate) (PMMA) hybrid thin film with loading content of merely 0.1 wt %. Our method provides an avenue toward mass production and full exploration of 2D QSs.

Infection and inflammation pathways regulated by lncRNAs were determined as the predominant pathogenetic factors underlying the SA. Finding that antisense lncRNAs have been either up- or down-regulated suggests that they may have both cis- and trans-regulations.

No abstract

Stereochemically and structurally complex cyclic dinucleotide-based stimulator of interferon genes (STING) agonists were designed and synthesized to access a previously unexplored chemical space. The assessment of biochemical affinity and cellular potency, along with computational, structural, and biophysical characterization, was applied to influence the design and optimization of novel STING agonists, resulting in the discovery of MK-1454 as a molecule with appropriate properties for clinical development. When administered intratumorally to immune-competent mice-bearing syngeneic tumors, MK-1454 exhibited robust tumor cytokine upregulation and effective antitumor activity. Tumor shrinkage in mouse models that are intrinsically resistant to single-agent therapy was further enhanced when treating the animals with MK-1454 in combination with a fully murinized antimouse PD-1 antibody, mDX400. These data support the development of STING agonists in combination with pembrolizumab (humanized anti-PD-1 antibody) for patients with tumors that are partially responsive or nonresponsive to singleagent anti-PD-1 therapy.

No abstract

No abstract